Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock
NCT ID: NCT02884011
Last Updated: 2025-01-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
133 participants
OBSERVATIONAL
2016-08-31
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock
NCT02876341
Effect of Vasopressin on Kidney and Cardiac Function in Septic Shock
NCT06125184
Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator
NCT06426407
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
NCT06122987
Systematic Adjunction of Vasopressine in Septic Shock
NCT07052084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No chronic antihypertensives
not on either a chronic β-blocker or ACE-Inhibitor
No interventions assigned to this group
β-blocker
on chronic β-blocker
No interventions assigned to this group
ACE-Inhibitor
on chronic ACE-Inhibitor
No interventions assigned to this group
Both β-blocker and ACE-inhibitor
on both chronic β-blocker and ACE-inhibitor
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of septic shock requiring vasopressor therapy (norepinephrine, epinephrine, phenylephrine, dopamine, or vasopressin)
* Admitted to an intensive care unit (ICU) at Rush University Medical Center (RUMC)
* Time frame: 01/01/2012 to 07/1/2016
Exclusion Criteria
* Transfer from outside hospital on vasopressors
* Admitted in cardiopulmonary arrest
* Prior arrest within 24 hours of admission to RUMC
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rush University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joshua DeMott, Pharm.D.
Role: PRINCIPAL_INVESTIGATOR
Rush University Medical Center
Ishaq Lat, Pharm.D.
Role: PRINCIPAL_INVESTIGATOR
Rush University Medical Center
Gourang Patel, Pharm.D.
Role: PRINCIPAL_INVESTIGATOR
Rush University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush Univeristy Medical Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16081001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.